Prevail Therapeutics skyrockets following agreement to be acquired by Eli Lilly Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Prevail Therapeutics (PRVL) up 85% after entering a definitive agreement for Eli Lilly to acquire the company for $22.50 per share in cash payable at closing plus one non-tradable contingent value right worth up to $4.00 per share in cash, for a total consideration of up to $26.50 per share in cash, or or an aggregate of approximately $1.04B.
- Eli Lilly (LLY) up 2% after announcing an agreement to acquire Prevail and raising its FY20 outlook
- Moderna (MRNA) up 1% after the FDA FDA said in briefing documents ahead of Thursday's advisory panel vote on the company's COVID-19 vaccine that the two-dose vaccination regimen was "highly effective in preventing PCR-confirmed COVID-19 occurring at least 14 days after receipt of the second dose"
- OncoCyte (OCX) up 62% after Burning Rock Biotech (BNR) announced that it entered into an exclusive licensing agreement with the company to bring DetermaRx, a risk stratification test for early stage lung cancer patients, to China
- Anavex (AVXL) up 20% after its ANAVEX2-73 trial in adult female patients with Rett syndrome
met primary and secondary endpoints
- Athenex (ATNX) up 7% after announcing that the FDA has approved Klisyri for the topical treatment of actinic keratosis on the face or scalp
LOWER -
- Mirum Pharmaceuticals (MIRM) down 19% after its 3.75M share secondary offering priced at $20.00
- Mesoblast (MESO) down 11% after announcing there was no reduction in recurrent non-fatal decompensated heart failure events in its DREAM-HF trial, which was the trial's primary endpoint
- GrafTech (EAF) down 6% after a 7M share block trade priced at $9.05
- Ocular Therapeutix (OCUL) down 2% after offering to sell $75M in common stock
Symbols:
PRVL LLY MRNA OCX AVXL ATNX MIRM MESO EAF OCUL Keywords: Fly Intel, Wall Street, Top Stories, Stocks